VETOQUINOL SA (VETO.PA) Stock Price & Overview

EPA:VETOFR0004186856

Current stock price

78.4 EUR
+0.1 (+0.13%)
Last:

The current stock price of VETO.PA is 78.4 EUR. Today VETO.PA is up by 0.13%. In the past month the price decreased by -4.62%. In the past year, price increased by 3.02%.

VETO.PA Key Statistics

52-Week Range68.7 - 91.5
Current VETO.PA stock price positioned within its 52-week range.
1-Month Range75.6 - 82.4
Current VETO.PA stock price positioned within its 1-month range.
Market Cap
931.392M
P/E
15.56
Fwd P/E
14.36
EPS (TTM)
5.04
Dividend Yield
1.14%

VETO.PA Stock Performance

Today
+0.13%
1 Week
-2.49%
1 Month
-4.62%
3 Months
-7.11%
Longer-term
6 Months -0.25%
1 Year +3.02%
2 Years -16.86%
3 Years -11.81%
5 Years -25.90%
10 Years +116.58%

VETO.PA Stock Chart

VETOQUINOL SA / VETO Daily stock chart

VETO.PA Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to VETO.PA. When comparing the yearly performance of all stocks, VETO.PA is a bad performer in the overall market: 74.97% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

VETO.PA Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to VETO.PA. VETO.PA is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

VETO.PA Earnings

Next Earnings DateApr 28, 2026
Last Earnings DateMar 27, 2026
PeriodQ2 / 2025
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %

VETO.PA Forecast & Estimates

11 analysts have analysed VETO.PA and the average price target is 95.12 EUR. This implies a price increase of 21.32% is expected in the next year compared to the current price of 78.4.

For the next year, analysts expect an EPS growth of 0.21% and a revenue growth -1.84% for VETO.PA


Analysts
Analysts80
Price Target95.12 (21.33%)
EPS Next Y0.21%
Revenue Next Year-1.84%

VETO.PA Groups

Sector & Classification

Sub-Industry
Pharmaceuticals
Index Membership

VETO.PA Financial Highlights

Over the last trailing twelve months VETO.PA reported a non-GAAP Earnings per Share(EPS) of 5.04. The EPS increased by 26.53% compared to the year before.


Income Statements
Revenue(TTM)532.39M
Net Income(TTM)60.08M
Industry RankSector Rank
PM (TTM) 11.28%
ROA 8.28%
ROE 10.59%
Debt/Equity 0.02
Chartmill High Growth Momentum
EPS Q2Q%5.9%
Sales Q2Q%-2.57%
EPS 1Y (TTM)26.53%
Revenue 1Y (TTM)-0.95%

VETO.PA Ownership

Ownership
Inst Owners14.01%
Shares11.88M
Float3.81M
Ins OwnersN/A
Short Float %N/A
Short RatioN/A

About VETO.PA

Company Profile

VETO logo image Vétoquinol SA operates as a global animal health company. The company is headquartered in Lure, Bourgogne-Franche-Comte. The company went IPO on 2006-11-16. The Company’s product portfolio is divided between livestock, such as cattle and pigs, and companion animals, including dogs and cats. Vetoquinol SA’s offering includes anti-infectives, such as Marbocyl; anti- pain inflammatories, which comprise Tolfedine, intended for dogs and cats, and Tolfine for livestock, and cardiovascular and nephrology treatment, such as Prilium, an oral daily administration formula for dogs, among others. The firm markets over 700 products, in such countries as France, Austria, Canada, Italy, Poland, Spain and the Netherlands, among others. The company trades its products throughout Europe, North America, Africa, the Middle East and Pacific Asia. In April 2014, it acquired Bioniche's animal health business.

Company Info

IPO: 2006-11-16

VETOQUINOL SA

Sainte-Anne 34 rue du Chene, Bp 189, Lure Cedex

Lure BOURGOGNE-FRANCHE-COMTE FR

Employees: 2519

VETO Company Website

VETO Investor Relations

Phone: 33384625555

VETOQUINOL SA / VETO.PA FAQ

What does VETO do?

Vétoquinol SA operates as a global animal health company. The company is headquartered in Lure, Bourgogne-Franche-Comte. The company went IPO on 2006-11-16. The Company’s product portfolio is divided between livestock, such as cattle and pigs, and companion animals, including dogs and cats. Vetoquinol SA’s offering includes anti-infectives, such as Marbocyl; anti- pain inflammatories, which comprise Tolfedine, intended for dogs and cats, and Tolfine for livestock, and cardiovascular and nephrology treatment, such as Prilium, an oral daily administration formula for dogs, among others. The firm markets over 700 products, in such countries as France, Austria, Canada, Italy, Poland, Spain and the Netherlands, among others. The company trades its products throughout Europe, North America, Africa, the Middle East and Pacific Asia. In April 2014, it acquired Bioniche's animal health business.


What is the current price of VETO stock?

The current stock price of VETO.PA is 78.4 EUR. The price increased by 0.13% in the last trading session.


What is the dividend status of VETOQUINOL SA?

VETOQUINOL SA (VETO.PA) has a dividend yield of 1.14%. The yearly dividend amount is currently 0.85.


What is the ChartMill technical and fundamental rating of VETO stock?

VETO.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


What is the Price/Earnings (PE) ratio of VETOQUINOL SA (VETO.PA)?

The PE ratio for VETOQUINOL SA (VETO.PA) is 15.56. This is based on the reported non-GAAP earnings per share of 5.04 and the current share price of 78.4 EUR.


What is the expected growth for VETO stock?

The Revenue of VETOQUINOL SA (VETO.PA) is expected to decline by -1.84% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.